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Abstract: 
 
Translational studies in rheumatology have seen many successes in the last decade with dramatic 
improvements in outcomes with the introduction of new biologically-based therapeutic agents for 
management of inflammatory diseases and the discovery of new monogenic disorders of 
inflammation.  Yet pharmacotherapy is still largely based on a trial-and-error approach with 
sequential use of therapies with different modes of action to find the most effective agent for an 
individual patient. Advances in molecular medicine combined with the drive towards precision care 
provide a significant opportunity to accelerate translation of biological understanding to the bedside. 
However, relative to the clinical component, where rheumatology is at the forefront of standardized 
data collection and measures of disease activity, standardized biologic sample collection and assay 
performance lag behind. Uniform approaches are required for robust collaborative research into 
pathobiology, especially for diseases where patient numbers at single institutions are small. 
Standardization is also critical to increase reproducibility between centers, which is a requisite step 
towards clinical implementation based on translational science. In the following discussion, we 
emphasize the need for standardization and best practices, 2) highlight current work and new 
directions in biospecimen science; and 3) review lessons learned from international networks.   
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The introduction of rheumatic disease therapies that selectively target cytokines or immune cell 
subsets has led to dramatic improvements in clinical outcomes for many paediatric and adult 
patients.1,2 However, to achieve the full potential of these and other immune interventions will 
require systematic characterization and classification of patients, incorporating both clinical and 
biologic measures. Heterogeneity among patients in rheumatic diseases is reflected in the fact that 
few therapies are effective in all patients carrying the same diagnosis, and this variable efficacy 
persists even within clinically defined subgroups of patients with a given disease.3 This heterogeneity 
is also reflected in the variations in results from molecular evaluations of patients with the same 
diagnosis, resulting in the equivalent of many diseases, each with smaller numbers, such that 
elucidating pathophysiology or identifying diagnostic or prognostic biomarkers is likely to require 
collaboration.  However the lack of reproducibility of many biomarker studies suggests that in 
addition to the true biological heterogeneity, additional procedural issues likely add substantial 
variability. Differences in biologic sample handling is one of the most common sources of site-
dependent results observed in current biomarker studies. Collaborative research involving multiple 
centers and groups requires harmonization of procedures to enable proper comparisons. The need 
for standardized operating procedures (SOP) for collection and handling of samples and data is a 
critical first step to ensure high-quality translational research. Sharing this information with 
researchers requires a flexible and secure data-sharing infra-structure supporting the integration of 
biologic data with precise clinical measures. 
 
Relative to the clinical component, where rheumatology is at the forefront of clinical data collection 
with use of standardized measures of disease activity and damage, there remains significant disparity 
in biologic sample collection and standardization of biologic measures of disease activity. 
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Internationally accepted measures of clinical disease activity and damage are widely used in both 
adult and pediatric rheumatic diseases and many have been incorporated as standard-of-care in 
clinical assessments.4 In contrast, biologic measures have not been incorporated at the bedside, 
despite evidence demonstrating that DNA, gene and protein expression and cellular 
immunophenotyping profiles help stratify patients and define homogeneous patient groups and point 
to molecular determinants of susceptibility and outcome in many rheumatologic diseases including 
childhood arthritis and rheumatic diseases.3,5, 6 Additional challenges arise when research is focused 
on rare diseases. Proper solutions require large-scale methodologic and organizational efforts aimed 
at bringing groups together that are able to collect, manage and share datasets. Uniform standards 
remove some of the barriers to sharing.  Addressing standardization throughout the life-cycle of 
clinical and biologic data will accelerate the incorporation of translational studies into clinical 
decision-making (Figure 1).  
 
Standardization and best practices guidelines 
Identification of robust biomarkers can dramatically improve diagnostic and treatment decisions. For 
example, the presence of anti-CCP antibodies have defined a subgroup of inflammatory arthritis.8 
Identification of biomarkers can be crucial in diagnostic and treatment decisions, yet variability can 
alter results of biological assays. Often specimen collection is perceived as the easy part of a protocol, 
yet validation of biomarkers relies on the control of error introduced during every step in the 
collection process (Figure 1). It is clear that in order to increase efficiencies and achieve appropriate 
sample sizes in translational studies, a concerted effort must be made to create a standard of practice 
for establishing common biobanking principles. In order to ensure the quality of downstream 
molecular analyses, potential variability due to biospecimen collection, processing and handling must 
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be identified and controlled by adhering to uniform SOPs.  Important lessons have been learned from 
both successes and failures in multicenter translational studies in pediatric rheumatology – 
highlighting the need for stringent procedures, processing times and quality control. 9,10   
 
Among the different types of experimental variability, preanalytical variations, including pre- and 
post- sample acquisition, are often not appreciated and thus not controlled.11,12  Preanalytical 
processes are defined as those procedures taking place between specimen collection and 
experimental assay/analysis. Even small differences in SOPs between groups or within groups could 
yield uninterpretable results due to variations at multiple steps in the collection and handling 
process.13  The National Cancer Institute’s Cancer Genome Atlas project was launched on the 
assumption that its researchers could obtain quality specimens provided by dozens of established 
biobanks with strong track records of success. Unfortunately, results indicated that very few of the 
initial samples were usable due to variability in collection, processing and storage in legacy 
biorepositories.13  Variables that may impact analytic outcomes include: 1) the type of blood 
collection tube and additive, 2) sample processing protocols, times and temperatures, 3) hemolysis, 4) 
transport conditions, 5) storage parameters (temperatures and freeze-thaw cycles). 14-16  These types 
of differences between samples have a significant impact on the stability of analytes causing 
deterioration in data quality. The challenge to harmonization of SOPs is to move forward with SOPs 
developed from the current state of the science and based on empirical evidence and not on ritual.  
 
Valuable lessons have been learned from international efforts addressing standardization of 
preanalytical biospecimen processing.17 The International Society for Biological and Environmental 
Repositories (ISBER) has produced harmonized high-quality best practices, which they publish and 
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update regularly [current version 2012].18  ISBER systematically reviews the biospecimen science 
literature, furnishing evidence and links to publications. Recommended protocols are available for 
collection and handling of a comprehensive list of biologic samples including cellular and noncellular 
fractions from human peripheral blood, but they clearly specify that SOPs must consider the analytical 
endpoints and available resources. Similarly, the Early Detection Research Network (EDRN) endorsed 
by the International Agency for Research on Cancer has also proposed similar SOPs for noncellular 
fractions from peripheral blood including plasma and serum in multi-institutional consortium 
environments.19 The HUPO Plasma Proteome project noted that plasma is the noncellular fraction of 
choice for interrogation of the proteome, with meticulous documentation of preanalytical steps to aid 
in decision-making for suitable downstream applications.16  
 
The recommendations from all these international organizations, however, focus exclusively on 
biospecimen collection from adult subjects. There are relatively few published biospecimen collection 
guidelines dealing with variables unique to children. Comparison to healthy controls needs to take into 
consideration age and stage of development, and biospecimen collection in children is more complex than 
simply decreasing the volume of specimens that are collected in adults. Even routine venipuncture can 
introduce a degree of preanalytical variability with the introduction of shear stress and the risk of cell and 
platelet activation, particularly with smaller gauge needles that are often used in young patients.20, 21  
Research ethics boards have their own policies around sampling in children with guidelines 
established around maximum allowable blood draw volumes based on body weight and approximate 
blood volumes.22 Increasing availability of multiplex assays designed with a small sample size in mind 
have been fortuitous for paediatric translational research. For example, multiplex immunoassays, 
such as Luminex, can detect up to 100 different proteins using as little as 50 ul sample volume23, and 
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high resolution, multiparameter immunophenotyping using mass cytometry quantified by time of 
flight (CyToF) can generate up to 35-parameter flow cytometry data from 1 ml of blood 24 making 
these types of platforms very useful where sample volumes are limited. These and other advances in 
biomolecular technology have greatly increased the power and precision of analytical tools used in 
immunologic research and have accelerated the drive toward personalized medicine. Human 
specimens that are analyzed using these emerging technology platforms are a critical resource for 
translational research in rheumatology because they are a rich source of biologic data from which 
molecular taxonomies can be derived and targets for therapy identified.25 
 
Biospecimen science 
Biospecimen science aims to determine the cellular and molecular alterations attributed to 
preanalytical processes.26 The main goal is to control variability and limit how it might affect 
downstream analytic results. It is possible to significantly reduce preanalytical variability by 
developing quality assurance and quality control measures specific for each type of sample or analyte, 
and to partner that with an informatics infrastructure capable of collecting the data needed to 
rigorously annotate the biospecimen collection and storage processes. A number of groups are active 
in biospecimen science (Table 1). The National Cancer Institute has spent almost a decade developing 
and revising Best Practice Guidelines for biospecimen resources which describes guiding principles 
that define the-state-of-the-science for biospecimen resource practices, promote biospecimen and 
data quality, and support adherence to ethical and legal requirements. Results from biospecimen 
research initiatives will inform future guidelines as the community moves toward the development of 
evidence-based SOPs that are both biospecimen-type and analysis-platform specific. The concept 
associated with ‘quality’ in a biospecimen cannot be uniquely defined, as these are critically 
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dependent on the downstream application or assay. Thus processing conditions that are optimal for 
one assay are not the same for another, necessitating careful documentation of preanalytical 
information and harmonization of the methods to document these conditions. The BRISQ 
(Biospecimen Reporting for Improved Study Quality) guidelines27 were developed in collaboration 
with the NCI Biospecimen Research Network to document where biospecimens came from and how 
they were treated. The guidelines list critical data elements that include general information for 
consistent documentation of categories of biospecimens and factors that might influence the 
integrity, quality, and/or molecular composition of biospecimens. Standardizing and codifying these 
elements for reporting and communication in scientific publications26 will serve to complement 
existing reporting recommendations. Tools to facilitate these processes are being developed, such as 
the Sample Preanalytical Code (SPREC), a specimen barcode with details about preanalytical sample 
processing.26 Recognizing and documenting these critical elements will further support evidence-
based biobanking, foster collaborations between biobanks, add rigor to scientific reporting, and also 
empower all stakeholders  involved in translational research by recognizing the importance of every 
step in biospecimen management. 
 
One critical element to document is the type of collection tube used for biosample collection.  Blood 
collection tubes (BCTs) have multiple components, all of which can affect the quality of the 
biospecimen and/or the performance of downstream assays.28 Different BCTs affect performance of 
multiple downstream assays including cytokine measurements by immunoassay to functional assays 
with PBMCs.  Supplementary Table 1 summarizes the pre-analytical variability associated with BCTs 
and the advantages and special considerations associated with different BCTs.  Supplementary Table 2 
describes biomarkers of interest in rheumatology and the pre-analytical variables directly affecting 
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them. 
 
Although international efforts to establish best practices for handling biospecimens have greatly 
contributed to convergence in principles for technical SOPs, some issues remain unsolved. One of the 
critical problems in preanalytic validation studies is the absence of key biomarkers that will predict 
sample integrity. Quality control (QC) assays are different depending on the sample type and 
downstream application. Consensus is needed on both quality control and uniformity of procedures. 
To illustrate, ribosomal RNA and RNA integrity number (RIN) are standard approaches for assessing 
RNA; however, neither method is sensitive nor specific enough to assess potential error in 
downstream gene expression analysis.29 Development and testing of various QC measures for 
biospecimens is in its infancy. ISBER endorsed a review of the literature,30 summarizing existing 
research on QC measures (preprocessing delay, freeze thawing, storage conditions) and assessing 
potential evidence-based QC assays summarizing potential QC biomarkers. CD40L and VEGF were 
identified as potentially meaningful analytes for assessing serum exposure to variations in 
temperatures for assessing serum freeze-thawing.30  However a caveat was that soluble CD40L levels 
are already artificially elevated in serum samples (which are not platelet free), and the increased 
sCD40L concentrations are a result of ex-vivo platelet activation during sample preparation and not 
due to in-vivo factors, therefore interpretation of studies of sCD40L already require caution.31 
Ascorbic acid has also been used as a QC marker for blood pre-centrifugation delay and serum storage 
conditions owing to its intrinsic instability.32,33 Pitfalls are readily apparent in even these examples of 
anlaytes proposed as potential QC tools.  
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To date, there is little information around acquisition and processing requirements for some 
downstream applications, particularly where the technology is relatively new (i.e. epigenomics, 
metabolomics, CyToF) or associated with specific functional assays. Tissue repositories need to be 
compliant with current regulations and aligned with current hypotheses and approaches but also 
flexible enough to allow for future testing. As an example, UK Biobank, following half a million 
participants, developed sample handling and storage protocols34 based on existing literature review 
and extensive validation studies with one of the main objectives to provide a resource that has 
applicability to a wide range of future scientific questions and technologies.35  
 
Lessons from biomarker discovery 
Biomarkers are important tools that have significant potential for guiding both clinical management of 
and therapeutic development for rheumatic diseases.  Although translational studies from DNA to 
RNA, protein and cellular phenotyping have contributed to identifying molecules as potential 
determinants of susceptibility and outcome in many rheumatologic diseases, to date, few have 
proven useful for predicting response to treatment. Pharmacotherapy is still largely based on a trial-
and-error approach with sequential use of therapies with different modes of action to find the most 
effective agent for an individual patient.36 However, a few analytes have shown promise at the 
bedside. These include S100 proteins37 and serum amyloid A (SAA),38 promising surrogate biomarkers 
that serve as non-specific measures of inflammation that may be able to detect subclinical disease 
activity.39,40, 41 One common advantage to S100 proteins and SAA is their ex-vivo stability. Blood 
samples can be collected, processed, stored using varying methods and the preanalytical variability 
has little effect on their measurement.  This is in stark contrast to TNF and IL-1, which play key 
roles in immunopathogenesis of rheumatic diseases but are unstable molecules and subject to 
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significant preanalytical variability. Although these mechanistic biomarkers point to molecular 
pathways directly involved in disease pathogenesis,42 technical limitations and preanalytical variability 
have prevented meaningful guidance for clinical decisions.  
 
A multi-centre international study, which included 364 patients from 29 countries, showed that serum 
levels of S100A8/9 (also called MRP8/14 or calprotectin) provide predictive value in children with 
juvenile idiopathic arthritis (JIA) who reach clinical remission on methotrexate, allowing health care 
professionals and families to estimate risk of flare after MTX is stopped.43 This biomarker also has 
some ability to predict flare of disease after stopping anti-TNF therapy.44  Both S100 A8/9 and S100 
A12 serum levels have been shown to be more accurate predictors of flare than the C reactive 
protein.39  Serum S100A8/9 measured before starting treatment with MTX has also been shown to 
have value in predicting good response to this first line DMARD in JIA,45 and decrease in S100A12 was 
associated with response to IVIG therapy in children with Kawasaki Disease, a multisystem vasculitis 
affecting young children.46 The search for predictive biomarkers with better sensitivity and specificity 
to guide treatment is ongoing: some early results are promising.47 An exciting development in 
systemic JIA, is a study showing that a panel of urine peptide biomarkers can discriminate between 
active and quiescent disease, if validated and shown to have predictive value this approach would 
have considerable benefit since it could be adapted to non-invasive testing.48 This echoes 
encouraging early results for urinary biomarkers associated with renal disease activity in systemic 
lupus erythematosis including neutrophil gelatinase-associated lipocalin and monocyte 
chemoattractant protein-1. 49 In a more rare disease, juvenile dermatomyositis (JDM) recent progress 
has been facilitated by international efforts to define clinical utility of myositis specific autoantibodies 
(MSA).50 Thus for example the MSA anti-MDA5 has been shown to be associated with an increased 
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risk of lung involvement and ulceration, yet mild muscle involvement, in both juvenile and adult 
DM.51,52 Identifying anti-MDA-5 positive patients can enable careful screening by CT scan to detect 
lung disease and allow early treatment of this devastating complication. Again this area of progress 
has been rapid in part due to the fact that the biological stability of the biomarker protein (antibody) 
in serum enables sharing and biomarker comparisons from a wide range of centres.  
 
Translational Research Networks 
Rheumatology has long embraced collaboration through many established national and international 
networks.  More recently, established research networks have joined together to tackle issues specific 
to translational research. For example, UCAN (Understanding Childhood Arthritis) is an international 
federation of research networks collectively representing over 50 countries and is committed to 
improving efficiencies by sharing complementary and collaborative research programs towards 
understanding the biology of clinical heterogeneity in childhood arthritis. UCAN was formed with the 
primary goal of harmonizing existing practices and creating a universally accepted standard for 
collection, processing, transfer, storage and access to biologic data linked to clinical information with 
a common minimal dataset for childhood arthritis. Using advances in evidence-based biospecimen 
science and international resources, UCAN is establishing best practice guidelines for preanalytical 
handling of biospecimens for use in translational studies in childhood arthritis and rheumatic diseases 
- a necessary prerequisite to incorporating biologic companion studies to clinical trials.  Optimizing 
access to high-quality biospecimens and their associated data is the first step towards integrating the 
rapidly expanding knowledge of fundamental disease mechanisms with data-intensive biology from 
omic analysis with clinical phenotype towards precision medicine. 
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Standardized best practices in clinical measures and biospecimens need to be curated by an 
information technology infra-structure that minimizes technical barriers to sharing while enabling 
control over important data access issues. Computerized tools and infrastructure to support the 
acquisition, management, communication and analysis of research data are more and more critical, as 
translational and clinical research become increasingly data intensive.53 A number of efforts are in 
progress to create information technology infrastructure for registry-based data-sharing. Examples 
from NIH sponsored research computing efforts with widespread uptake include REDCap (Research 
electronic data capture) 54 and i2B2 (Integrating Biology and the Bedside),55 both freely available 
software solutions. When sharing between registries and biobanks is necessary, the hurdles are 
challenging with differences in terminology, data collections and database structure. Data standards 
facilitate data sharing, but flexibility and nimble responses to practical day-to-day tasks dictate end-
user uptake.  This tension between requirements for standard methods of naming and manipulating 
data and the practical functionality of the software solution is ubiquitous, leading to different 
solutions used by different researchers. Software solutions have also been developed to tackle these 
challenges – BiobankConnect is one example of a system that rapidly connects data elements for 
pooled analysis across different biobanks and software solutions by semi-automatically matching 
desired data elements with available ones using indexing terms and algorithms.56 Standardized, 
collaborative digital infrastructure and advances in information technology tools to accelerate cross-
platform searches are key enhancements to the data gathering process in the translational medicine 
pipeline (Figure 2). 
  
Collaboration and sharing of biologic samples and resources goes beyond providing access to data.  
Good sharing requires quality control for not only the sample but also documentation, metadata and 
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a clear framework for access. This is costly and requires dedicated resources to address barriers, but is 
not always recognized nor valued in our current academic settings. Legal, ethical and funding 
challenges present as fundamental barriers that precede collaboration and sharing.  One of the goals 
of a European Union funded initiative – the SHARE (Single Hub and Access point for paediatric 
Rheumatology in Europe) project – aims to specifically identify and resolve the barriers preventing 
effective multi-national collaboration.  In the USA, one approach to streamline ethics review is Reliant 
Review.  A Reliant Review is a process that allows investigators to collaborate across institutions in a 
more efficient way by allowing a single institution to provide ethics review for a research project that 
involves multiple sites.  The institutional review board (IRB) that performs the ethics review is 
designated the ‘IRB of Record’ and collaborating organizations agree to accept this review and are 
designated as the ‘Relying IRBs’, making the process more efficient and streamlined.   
 
Lack of funding and recognition is another obstacle to effective sharing of biospecimens. This is 
amplified in the study of rare diseases, where the work-load for individual centers may be heavy with 
regard to protocols, translated informed consent forms and local ethical approvals, despite the fact 
that sometimes only one or two patients will be recruited from each center.  The European 
Commission has recently recognized that research data are as important as publications and has 
incorporated this principle in current funding schemes.57  Additionally, the pan-European initiative, 
The Biobanking and Biomolecular resources Research Infrastructure (BBMRI-ERIC) is exploring ways to 
encourage the biobanking research community through harmonized citation and recognition 
processes.58  Working together with scientific journal editors, guidelines for the standardized citation 
of bioresources in journal articles (CoBRA) have been proposed.58 
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Moving beyond a clinical and descriptive understanding of rheumatic diseases will require partnership 
with biology. We have reviewed some key ingredients for success in overcoming the hurdles in 
translational research, which include gathering, integrating and sharing data, with standardization as 
the fundamental underlying principle. Sharing of biologic and health-related data for biomedical 
research is of utmost importance in securing continued advancement in our understanding of human 
health and disease. The challenges associated with international collaborative translational research 
require a commitment to developing a sharing framework that will facilitate responsible and excellent 
research with evidence-based standards and guidelines.25 Now is the time.  In order to maximise the 
opportunities for advances in molecular medicine, and move towards evidence-based precision 
decisions for treatment, it is vital to accelerate these harmonization and standardization efforts.   
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Figures Legends: 
 
Figure 1: Biospecimen Science - Standardized operating procedures for collection and handling of 
samples and data is a critical first step to ensure high quality translational research. Preanalytical 
variables impact various steps from specimen collection to downstream analysis.  These include 1) 
The physiology of the subject; 2) Uniformity in biospecimen collection; 3) Biospecimen handling 
procedures, illustrated in yellow, blue and red, respectively.  Quality control measures may be 
diagnostic of upstream collection, processing and/or storage processes, or a predictive assay for the 
validity of the downstream analysis. (Adapted from reference 30)  
   
Figure 2. Translational Research Pipeline – Resources and infra-structure support the start the of the 
translational medicine pipeline with fundamental studies and applied research that define molecular 
and cellular mechanisms and their relationship to disease. Data is generated, analyzed and integrated 
creating a knowledge network with the evidence to impact clinical decisions. (Adapted from reference 
25)  
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Table 1: Summary of select international biospecimen collection, storage, handling and sharing best 
practices and guidelines 
 
Institution Document(s) and select references Recommendations 
International Society 
for Biological and 
Environmental 
Biorepositories 
 Best practice guidelines for 
repositories: collection, storage, 
retrieval and distribution of biological 
materials for research18 
 Standard preanalytical coding for 
biospecimens defining the sample 
PREanalytical code (SPREC)26 
 Identification of evidence-based 
biospecimen quality control tools30 
 Adhere to recommended 
best practice guidelines 
 Annotate standard 
operating protocols with 
SPREC codes 
National Cancer 
Institute (NCI), Office 
of Biorepositories and 
Biospecimen Research 
(OBBR), United States 
 Best practices for biospecimen 
resources59 
 Biospecimen reporting for improved 
study quality (BRISQ)27 
 Include BRISQ guidelines in 
translational research 
studies 
Biobank 
Standardization and 
Harmonisation for 
Research Excellence in 
the European Union 
(EU-BioSHaRE) 
 Ethical, legal and social implications 
of data and sample sharing, 
framework, tools and policies60 
 
 Adapt framework, tools 
and policies to strengthen 
institutional ethical, legal 
and social policies  
UK Biobank, Ltd. 
 Sample handling and storage 
protocols34  
 The UK Biobank sample handling and 
storage validation studies35 
 Design and implementation of a 
high-throughput biological sample 
processing facility61 
 Review protocols and 
validation studies for 
informed, evidenced-based 
decision making around 
translational research 
study design 
The Australasian 
Biospecimen Network 
 Australasian Biospecimen Network 
Biorepository Protocols – 4th 
Revision62 
 Review protocols for 
informed decision making 
around translational 
research study design 
Understanding 
Childhood Arthritis 
Network (UCAN) 
International 
Federation 
 Best practice guidelines for the 
collection, processing, transfer, 
storage and access to biologic data 
linking to clinical information in 
childhood arthritis63 
 Review protocols for 
informed decision making 
around paediatric 
translational research 
study design 
Biobanking and 
Biomolecular 
resources Research 
Infrastructure (BBMRI-
ERIC), pan-European 
research infrastructure 
 A minimum data set for sharing 
biobank samples, information, and 
data: MIABIS64 
 BBMRI subgroup – Bioresource 
Research Impact Factor: Developing 
a guideline to standardize the 
citation of bioresources in journal 
articles (CoBRA)58 
 Adhere to the proposed 
standardized methods for 
citing bioresources in 
journal articles 
Canadian Tumour  Certification for biobanks65  Ensure biobanks are 
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Repository Network 
(CTRNet) 
 Comprehensive set of standard 
operating procedures for a 
biorepository network66 
certified to meet the 
standard requirements for 
a biorepository network 
Global Alliance for 
Genomics and Health, 
Regulatory and Ethics 
Working Group 
 Framework for responsible sharing of 
genomic and health-related data67 
 Maintain an awareness of 
the potential impact on 
sharing genomic and 
health-related data 
Single Hub and Access 
point for paediatric 
Rheumatology in 
Europe (SHARE) 
Project 
 Paediatric rare diseases project 
 Work package dedicated to ethical 
and legal barriers with multi-national 
collaborations 
 Use the proposed 
strategies to overcome 
international ethical and 
legal barriers  
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Supplemenarey Table 1: Pre-analytical variability with blood collection tubes (BCT) 
 
Tube Advantages Potential Limitations 
EDTA  Hematology testing28 
 Proteomic analysis16 
 DNA studies 
 Cytogenetic assays 
 Immunoassays 
 Binds required reagents and co-factors68   
 Affects antibody binding68 
 
Heparin  PBMC Immediate isolation for 
functional assays 
 Lithium heparin is recommended 
over sodium heparin for 
downstream T cell assays 69 
 Ag-Ab reactions (slows interaction) 70 
 Cryoprotein measurement (precipitates 
cryoprotein) 28 
 Albumin measurements71 
 Creatine kinase, -glutamyl transferase72 
 
Citrate  Coagulation testing73 
 Citrate-stabilized blood results in 
better quality RNA and DNA, yields 
more lymphocytes for culture 
 
 Aspartate aminotransferase 
 Alkaline phosphatase73 
 
Serum Separator Tubes 
(SST) 
 Serum testing including S100 
proteins and antibodies 
 Hydrophobic drugs including phenytoin, 
phenobarbital, carbamazepine, etc 
(absorbed by gel) 74 
 Myoglobin and CK-MB75 
 Testosterone 
 
P100 (additive: 
protease inhibitor 
cocktail) 
 Well suited for proteomic studies, 
including analysis of unstable 
proteins (ie TNF)76 
 Provides an option for delayed 
processing after blood collection 
 Gel stopper malfunction could interfere 
with sample 
 Potential for hemolysis 
 Cost 
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Supplementary Table 2: Pre-analytical variables affecting biomarker measurements 
 
Biomarkers Pre-analytical variable and impact21 
CYTOKINES: 
IL-1, IL-1B, IL-2, IL-4, IL-5, IL-6, IL-13, 
IL-15, IL-17, IL-18, TNF, INF, CXCL-823 
 Cytokine stability is affected by additives in the blood collection 
tube (serum, sodium heparin plasma, EDTA plasma, sodium 
citrate plasma23, P100 plasma76) 
PLATELET DERIVED PROTEINS: 
CD40L, VEGF, MMPs31,77 
 Platelet derived proteins are falsely elevated in serum due to 
platelet release during activation and/or coagulation process 
MATRIKINES: 
 MMP-1, MMP-2, MMP-13 
 MP-2, MMP-9 
 Matrikines are generally elevated in plasma (regardless of blood 
collection tube) due to isolation dependent activation of 
neutrophils and mononuclear cells78,79 
OTHER BIOMARKERS: 
 Troponin 
 Glucose 
 
 Other biomarkers are decreased in plasma from heparinized 
tubes due to binding8 
 Other biomarkers are decreased in plasma (regardless of blood 
collection tube) due to an anticoagulant-induced fluid shift from 
erythrocytes to plasma9 
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